科研之友
微信
新浪微博
Facebook
分享链接
摘要
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is an effective therapy to reduce low-density lipoprotein cholesterol and cardiovascular events. A recent study shows that 1 or 2 doses of inclisiran, a long-acting synthetic small-interfering RNA that selectively targets hepatic PCSK9, causes a sustained reduction of plasma low-density lipoprotein cholesterol for <= 6 months. Pending further studies of safety and efficacy, this may represent an important addition to the armamentarium for inhibiting PCSK9.
- 出版日期2017-3-31
